证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2026-001 问 2：公司目前的研发思路以及在研品种的进展情况？ 答：公司立足生物制药领域，坚持创新引领公司发展的 策略，内部挖掘研发潜力，外部对接先进技术，积极与国内 外知名学者、专家合作，推动产学研联动和技术合作等工作， 形成"自主创新+外部引进"的研发模式。目前公司在研产 品的临床试验正在积极推进中，其中"HuA21 注射液"是公 司自主研发的 HER2 靶点的一款新药，与曲妥珠单抗联用可 协同增加肿瘤抑制效果，前期探索性研究阶段性数据呈现出 较好的安全性和疗效，已顺利完成 Ib/II 期临床研究的受试 者入组，将根据中期分析结果计划开展 III 期临床研究，目 前 III 期临床试验方案讨论会已经召开；"AK2024 注射液" 是公司开发的针对 HER2 靶点的创新药物，目前正在开展 I 期临床试验，临床前研究表明，"AK2024 注射液"可抑制 HER2 阳性肿瘤细胞的增殖，在增强曲妥珠单抗对肿瘤生长的 抑制作用方面，其协同效应明显优于帕妥珠单抗；"HK010 注射液"是公司开发的"PD ...

经济观察网 安科生物（300009）近期在药品集采及创新药研发方面取得多项进展。 抗感染药物AK1012项目（干扰素α2b吸入溶液）正在开展II/III期临床试验。 参股公司博生吉安科的PA3-17注射液（CD7-CAR-T疗法）被纳入突破性治疗品种，处于关键II期临床； 元宋生物的"重组L-IFN腺病毒注射液"推进至IIa期。 与阿法纳合作的AFN0328注射液（治疗HPV相关病变）完成I期临床，属首创药物。 战略推进 股票近期走势 国家集采接续采购中选：2026年2月11日，公司公告其阿托西班注射剂（适用于推迟早产）和丙酚替诺 福韦口服常释剂型（适用于慢性乙型肝炎）拟中选国家组织药品集采协议期满品种接续采购。采购周期 计划至2028年12月31日，若后续合同落地，可能对销售量及市场占有率产生积极影响。 产品研发进展 在研产品临床试验推进：根据2026年2月6日公司披露，多项创新药研发取得进展： HER2靶点药物如HuA21注射液（已完成Ib/II期入组，计划III期）、AK2024注射液（I期临床）和HK010 双抗（II期首例入组）正处于关键阶段。 生长激素领域，AK2017注射液（重组人生长激素-Fc ...

Core Viewpoint - Anke Bio (300009.SZ) has officially shipped its long-acting follicle-stimulating hormone in early November, and the company is currently in the process of collecting market sales data and performance metrics [1] Group 1 - The long-acting follicle-stimulating hormone has been shipped as of early November [1] - The company is gathering information on market sales and sales data [1]

Core Viewpoint - Anke Bio (300009.SZ) has officially shipped its long-acting follicle-stimulating hormone in early November, and the company is currently in the process of collecting market sales data and performance metrics [1] Group 1 - The long-acting follicle-stimulating hormone has been shipped as of early November [1] - The company is gathering information on market sales and sales data [1]

Core Viewpoint - Anke Bio has been actively involved in the reproductive health sector for years, with a comprehensive product range from reproductive testing to therapeutic drugs, and aims to leverage a partnership with Baoji Pharmaceutical for market expansion [1] Group 1: Company Strategy - The company has established a dedicated reproductive and antiviral division to promote market segmentation and enhance product visibility [1] - A specialized team of over 300 members is in place to support the marketing efforts for the long-acting follicle-stimulating hormone once it is launched [1] Group 2: Product Development - The long-acting follicle-stimulating hormone is expected to generate significant revenue by the year 2026 [1] - The company is currently in the process of regulatory review for the long-acting growth hormone in collaboration with Weisheng Pharmaceutical [1] - The company anticipates that both the long-acting growth hormone and the long-acting follicle-stimulating hormone will quickly enter the market, providing new growth opportunities for its business performance [1]

Core Viewpoint - Anke Biotech reported a decline in net profit for the first half of the year, primarily due to increased promotional and R&D expenses, despite stable revenue growth in its main business segment [1] Financial Performance - The company achieved a net profit attributable to shareholders of 367 million yuan, a year-on-year decrease of 11.92% [1] - The non-recurring net profit attributable to shareholders was 342 million yuan, down 12.38% year-on-year [1] - Revenue remained stable, with the main business segment of biological products generating 969 million yuan, reflecting a year-on-year growth of 7.49% [1] Product Development and Market Position - The company's first antibody drug, trastuzumab injection "Ansaiting," experienced rapid sales growth, with revenue increasing by 298% year-on-year, becoming a key driver of performance [1] - The company actively expanded its product matrix through business development collaborations, introducing two significant long-acting products during the reporting period [1] - The exclusive introduction of long-acting follicle-stimulating hormone strengthens the company's position in the assisted reproduction sector [1] Future Outlook - The company is viewed positively for its long-term development potential, maintaining a "buy" rating [1]